The blood–brain barrier (BBB) is the interface between the central nervous system and
systemic circulation. It tightly regulates what enters and is removed from the brain …

Globally, stroke is a leading cause of death and long-term disability. Over the past decades,
several efforts have attempted to discover new drugs or repurpose existing therapeutics to …

Purpose Drugs promoting myelin repair represent a promising therapeutic approach in
multiple sclerosis and several candidate molecules are currently being evaluated, fostering …

Overcoming the efflux mediated by ATP–binding cassette (ABC) transporters at the blood-
brain barrier (BBB) remains a challenge for the delivery of small molecule tyrosine kinase …

Only partial deficiency/inhibition of P-glycoprotein (P-gp, ABCB1) function at the blood-brain
barrier (BBB) is likely to occur in pathophysiological situations or drug-drug interactions. This …

Domperidone and metoclopramide are widely prescribed antiemetic drugs with distinct
neurological side effects. The impact of P-glycoprotein (P-gp)-mediated efflux at the blood …

The P-glycoprotein (P-gp/ABCB1) is a major efflux transporter which impedes the brain
delivery of many drugs across the blood-brain barrier (BBB). Focused ultrasound with …

PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of this
efflux transporter in effectively restricting the brain penetration of its substrates across the …

Background Intracellular tension plays a crucial role in the destruction of the blood–brain
barrier (BBB) in response to lesion stimuli. Tight junction structure could be primarily affected …

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict at the blood–
brain barrier (BBB) the brain distribution of the majority of currently known molecularly …